Transduction of human neural progenitor cells using recombinant adeno-associated viral vectors

P. Wu, Y. Ye, C. N. Svendsen

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


Human neural progenitor cells (hNPCs) represent an attractive source for cell therapy of neurological disorders. Genetic modification of hNPCs may allow a controlled release of therapeutic proteins, suppress immune rejection, or produce essential neurotransmitters. In search of an effective gene delivery vehicle, we evaluated the efficiency of a recombinant adeno-associated viral (rAAV) vector expressing enhanced green fluorescent protein (CAGegfp). Our study demonstrated that CAGegfp efficiently transduced both proliferating and differentiated hNPCs in vitro. EGFP expression was detected as early as 1 day after exposure to CAGegfp and was detectable for up to 4 months. Following transduction, the growth rate of hNPCs slowed down, but they were still able to differentiate into neurons and glia. Furthermore, CAGegfp-modified hNPCs survived, differentiated and expressed EGFP after transplanting into spinal cord of adult rats. Our results indicated that rAAV vectors might be a useful tool in hNPC-based cell and gene therapy for neurological disorders.

Original languageEnglish (US)
Pages (from-to)245-255
Number of pages11
JournalGene Therapy
Issue number4
StatePublished - 2002


  • Adeno-associated virus
  • Green fluorescent protein
  • Human neural progenitor cells
  • Rat
  • Spinal cord
  • Transplantation

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics


Dive into the research topics of 'Transduction of human neural progenitor cells using recombinant adeno-associated viral vectors'. Together they form a unique fingerprint.

Cite this